Search results
Results from the WOW.Com Content Network
The word liposome derives from two Greek words: lipo ("fat") and soma ("body"); it is so named because its composition is primarily of phospholipid.. Liposomes were first described by British hematologist Alec Douglas Bangham [10] [11] [12] in 1961 at the Babraham Institute, in Cambridge—findings that were published 1964.
Cationic liposomes are spherical structures that contain positively charged lipids. Cationic liposomes can vary in size between 40 nm and 500 nm, and they can either have one lipid bilayer (monolamellar) or multiple lipid bilayers (multilamellar). [ 1 ]
The hydrophobic ends of phospholipid molecules are constrained [clarification needed], often to each other, creating spherical liposomes that are smaller when the hydrophobic ends are exposed to a solution that is aqueous in nature. The preparation of liposomes results in the formation of the liposome extruder [clarification needed]. A liposome ...
The 2013 Nobel Prize in Physiology or Medicine was shared by James Rothman, Randy Schekman and Thomas Südhof for their roles in elucidating (building upon earlier research, some of it by their mentors) the makeup and function of cell vesicles, especially in yeasts and in humans, including information on each vesicle's parts and how they are assembled.
Liposomes have a lipid outer layer that can be used to bind ligands. Conjugation of the ligand to the surface of a liposome can be achieved through multiple routes. Covalent binding [ 5 ] [ 6 ] is a prominent way due to the anchoring between the long-chain fatty acids and the ligand.
Unilamellar liposomes are used to study biological systems and to mimic cell membranes, and are classified into three groups based on their size: small unilamellar liposomes/vesicles (SUVs) that with a size range of 20–100 nm, large unilamellar liposomes/vesicles (LUVs) with a size range of 100–1000 nm and giant unilamellar liposomes ...
Immunoliposome therapy is a targeted drug delivery method that involves the use of liposomes (artificial lipid bilayer vesicles) coupled with monoclonal antibodies to deliver therapeutic agents to specific sites or tissues in the body. [1]
As such, liposomes, polymersomes, nanoparticles, microcapsules and a number of other particles can qualify as artificial cells. The terms "artificial cell" and "synthetic cell" are used in a variety of different fields and can have different meanings, as it is also reflected in the different sections of this article.